Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Total Valuation
Akebia Therapeutics has a market cap or net worth of $685.48M. The enterprise value is ―.
Market Cap$685.48M
Enterprise Value―
Share Statistics
Akebia Therapeutics has 262,635,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding262,635,830
Owned by Insiders2.21%
Owned by Institutions8.30%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is 1.41 and return on invested capital (ROIC) is -36.11%.
Return on Equity (ROE)1.41
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-36.11%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee884.97K
Profits Per Employee-383.48K
Employee Count181
Asset Turnover0.73
Inventory Turnover3.89
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is -5.77. Akebia Therapeutics’s PEG ratio is 0.12.
PE Ratio-5.77
PS Ratio0.00
PB Ratio-8.19
Price to Fair Value-8.15
Price to FCF-12.27
Price to Operating Cash Flow-9.91
PEG Ratio0.12
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.
Revenue160.18M
Gross Profit97.00M
Operating Income-50.47M
Pretax Income-69.41M
Net Income-69.41M
EBITDA-13.72M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was -40.66M and capital expenditures -2.00K, giving a free cash flow of -40.66M billion.
Operating Cash Flow-40.66M
Free Cash Flow-40.66M
Free Cash Flow per Share-0.15
Dividends & Yields
Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change126.96%
50-Day Moving Average2.13
200-Day Moving Average1.82
Relative Strength Index (RSI)64.68
Average Volume (3m)4.24M
Important Dates
Akebia Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Akebia Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of -96.86%
Current Ratio1.41
Quick Ratio1.21
Debt to Market Cap<0.01
Net Debt to EBITDA3.52
Interest Coverage Ratio-2.78
Taxes
In the past 12 months, Akebia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is -25.69, with an EV/FCF ratio of -8.66.
EV to Sales2.20
EV to EBITDA-25.69
EV to Free Cash Flow-8.66
EV to Operating Cash Flow-8.67
Balance Sheet
Akebia Therapeutics has $51.87M in cash and marketable securities with $47.64M in debt, giving a net cash position of -$4.23M billion.
Cash & Marketable Securities$51.87M
Total Debt$47.64M
Net Cash-$4.23M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.51
Margins
Gross margin is 60.08%, with operating margin of -31.51%, and net profit margin of -43.33%.
Gross Margin60.08%
Operating Margin-31.51%
Pretax Margin-43.33%
Net Profit Margin-43.33%
EBITDA Margin-8.57%
EBIT Margin-31.98%
Analyst Forecast
The average price target for Akebia Therapeutics is $6.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.63
Price Target Upside154.02% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-17.75%
EPS Growth Forecast-19.17%